Serina Therapeutics Inc (SER) Stock News

Boyd Group Services Inc. announced a cash dividend of C$0.156 per common share for the second quarter of 2026, payable on July 29, 2026 to shareholders of record as of June 30, 2026. The company operates one of North America's largest non-franchised collision repair center networks under brands including Boyd Autobody & Glass, Gerber Collision & Glass, and Glass America.

Axon Enterprise is expanding into the law enforcement drone and robotics market, estimated at $20 billion. The company has partnered with Skydio and acquired Dedrone to build its drone solution. With existing relationships across U.S. public agencies, strong AI revenue growth (700% YoY), and $14.3 billion in future bookings, analysts project 30% annual earnings growth. The stock is trading 49% below its August 2025 high at a 54x 2026 earnings multiple.

Comstock Resources sold a 27% non-controlling equity interest in its midstream subsidiary Pinnacle Gas Services to Sixth Street for $600 million, valuing Pinnacle at $2.2 billion enterprise value. Comstock retained 73% controlling interest and used proceeds to eliminate all Pinnacle debt and preferred equity while reducing annual fixed charges by approximately $40 million. The transaction strengthens Comstock's balance sheet and validates the value of its Western Haynesville acreage.

The FDA has accepted Roche's New Drug Application for giredestrant, an oral selective estrogen receptor degrader (SERD), for treating ER-positive, HER2-negative early-stage breast cancer under priority review. Phase III lidERA trial data showed giredestrant reduced the risk of invasive disease recurrence or death by 30% compared to standard-of-care endocrine therapy, representing the first major advance in adjuvant endocrine therapy in over 20 years. An FDA decision is expected by November 30, 2026.

Stewart Information Services Corporation (NYSE: STC) announced a cash dividend of $0.525 per share for Q2 2026, payable on June 30, 2026, to shareholders of record as of June 15, 2026. The global real estate services company continues its dividend distribution to common stockholders.

Gossamer Bio (GOSS) faces a securities class action lawsuit after its Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing an 80% stock price drop. The lawsuit alleges the company misled investors about trial design and patient recruitment, particularly regarding heavily-treated patients in Latin America sites showing outsized placebo responses that compressed treatment efficacy.

98% Year-Over-Year Revenue Growth; Company Achieves Net Income Profitability; Secures Two Landmark Global Enterprise Agreements VANCOUVER, BC , May 28, 2026 /CNW/ - RESAAS Services Inc. ("RESAAS" or "the Company") (TSXV: RSS ) (OTCQB: RSASF ), a technology company modernizing collaboration, payments, and data exchange across the global real estate industry, today announced its financial results for the first quarter ended March 31, 2026. The Company delivered a record revenue quarter on a year-over-year basis, achieved net profitability, and expanded its enterprise client roster with two globally recognized real estate brands, underscoring the growing commercial validation of its platform. Q1 2026 FINANCIAL & OPERATIONAL HIGHLIGHTS Revenue of $302,470 in Q1 2026, representing 98% growth year-over-year compared to $152,681 in Q1 2025 Net income of $8,627 in Q1 2026, a $77,672 improvement versus a net loss of $(69,045) in Q1 2025 — marking a significant inflection toward profitability Positive operating cash flow of $6,593 for the quarter Cash position increased to $63,373 at March 31, 2026, up from $42,527 at December 31, 2025, driven by revenue collections Working capital deficiency improved by $15,260 quarter-over-quarter to $(891,312) at March 31, 2026 Savills, a leading global real estate services firm, selected RESAAS to power its new global referral platform (February 2026) Chestertons, an internationally recognized real estate brand, selected RESAAS to power its global referral platform (March 2026) Snowflake integration launched, enabling enterprise customers to synchronize RESAAS data into Snowflake's AI Data Cloud Subsequent to quarter-end: closed a $1,800,000 non-brokered private placement at $0.45 per share (April 20, 2026), strengthening the balance sheet FINANCIAL RESULTS Selected Financial Data (CAD$) Q1 2026 Q1 2025 Revenue $302,470 $152,681 Net Inc

Gossamer Bio (GOSS) faces a securities class action lawsuit after its Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing an 80% stock price drop. The lawsuit alleges the company misled investors about trial design and patient recruitment, particularly regarding heavily-treated patients in Latin America sites showing outsized placebo responses that compressed treatment efficacy.

Universal Health Services, Inc. (NYSE:UHS) announced that its Board of Directors approved a cash dividend of $0.20 per share payable on June 18, 2026 to shareholders of record as of June 8, 2026.

CU Inc. announced that holders of Series 4 Preferred Shares will not be able to convert into Series 5 Preferred Shares, as only approximately 625 shares were tendered for conversion against the required one million shares threshold. The Series 4 Preferred Shares will continue paying a fixed quarterly dividend at an annual rate of 4.573% for the five-year period beginning June 1, 2026.

The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market was valued at USD 1.5 billion in 2025, with the US representing the largest market share. Recent FDA approvals include VEPPANU (vepdegestrant), the first PROTAC therapy, while several emerging therapies are in clinical development.

Gossamer Bio (GOSS) faces a securities class action lawsuit after its Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing an 80% stock price decline. The lawsuit alleges the company misled investors about trial design and patient recruitment, particularly regarding heavily-treated patients in Latin America sites showing outsized placebo responses that compressed treatment efficacy.